Kestra Advisory Services LLC Makes New $1.55 Million Investment in Celcuity, Inc. $CELC

Kestra Advisory Services LLC bought a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the first quarter, Holdings Channel reports. The firm bought 13,604 shares of the company’s stock, valued at approximately $1,553,000.

Several other institutional investors and hedge funds have also modified their holdings of CELC. EverSource Wealth Advisors LLC increased its stake in shares of Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE boosted its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Celcuity in the fourth quarter valued at about $42,000. Finally, Ogorek Anthony Joseph NY ADV increased its position in Celcuity by 19.7% in the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Citizens Jmp raised their price target on Celcuity from $160.00 to $177.00 and gave the stock a “market outperform” rating in a research note on Wednesday, July 15th. Needham & Company LLC reissued a “buy” rating and issued a $157.00 price target on shares of Celcuity in a research note on Friday, May 15th. Leerink Partners set a $155.00 price objective on Celcuity in a report on Tuesday, June 2nd. Stifel Nicolaus set a $150.00 price objective on Celcuity in a report on Monday, May 4th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a research report on Wednesday, July 15th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Celcuity has a consensus rating of “Moderate Buy” and a consensus target price of $155.18.

Celcuity Trading Up 4.2%

NASDAQ:CELC opened at $91.69 on Wednesday. The company’s 50 day moving average is $106.76 and its 200-day moving average is $110.72. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 12 month low of $13.50 and a 12 month high of $151.02. The firm has a market cap of $4.47 billion, a price-to-earnings ratio of -23.51 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.10. Equities analysts anticipate that Celcuity, Inc. will post -3.76 EPS for the current year.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by insiders.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.